All In Biotech

Drug Trial Radar · NCT07848191

Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis

A Phase 4, Open-label, Multi-group Study of Rezdiffra® in Combination With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and Moderate to Advanced (F2-F3) Fibrosis, Administered According to Their Approved Labeling

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 7, 2026

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Madrigal Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Sep 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)

Conditions

  • MASH - Metabolic Dysfunction-Associated Steatohepatitis

Interventions

  • RezdiffraDrug

    All study medications will be administered according to their labels: • REZDIFFRA- Label weight-based dosing: * \<100 kg: 80 mg orally once daily. * ≥100 kg: 100 mg orally once daily

  • ResmetiromDrug

    Resmetirom - weight-based dosing: * \<100 kg: 80 mg orally once daily. * ≥100 kg: 100 mg orally once daily

  • ACTOS/pioglitazoneDrug

    Label dosing recommendations indicated for patients without congestive heart failure (15 or 30 mg orally once daily; if tolerated, increase by 15 mg increments up to a maximum of 45 mg orally once daily for additional glycemic control

  • FARXIGA/dapagliflozinDrug

    Label dosing recommendations indicated for glycemic control in type 2 diabetes (5 mg orally once daily; if tolerated, increase to 10 mg orally once daily for additional glycemic control)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From First Dose of newly introduced medication up to 28 weeks
  2. Number and Percentage of Participants With TEAEs by Maximum SeverityTime frame: From First Dose of newly introduced medication up to 28 weeks
  3. Number and Percentage of Participants With TEAEs by Relationship to Study MedicationTime frame: From First Dose of newly introduced medication up to 28 weeks

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Liver Health - Chandler

    Chandler, Arizona · Recruiting

  • Arkansas Gastroenterology

    North Little Rock, Arkansas · Recruiting

  • Southern California Research Center

    Coronado, California · Not yet recruiting

  • Inland Empire Liver Foundation

    Rialto, California · Recruiting

  • Florida Research Institute

    Lakewood Rch, Florida · Recruiting

  • Gastro Health PLLC Galloway

    Miami, Florida · Recruiting

  • Med Research of Florida, LLC

    Miami, Florida · Not yet recruiting

  • Elevate Clinical Research

    Lake Charles, Louisiana · Recruiting

  • Centricity Research - Morehead City - Multispecialty - PPDS

    Morehead City, North Carolina · Recruiting

  • Gastro Health Research

    Cincinnati, Ohio · Recruiting

  • University Diabetes and Endocrine Consultants

    Chattanooga, Tennessee · Not yet recruiting

  • Texas Clinical Research Institute

    Arlington, Texas · Recruiting

  • South Texas Endocrinology & Metabolism Center

    Corpus Christi, Texas · Recruiting

  • The Liver Institute at Methodist Dallas Medical Center

    Dallas, Texas · Recruiting

  • Elevate Clinical Research - McAllen - PPDS

    McAllen, Texas · Not yet recruiting

  • Diabetes and Glandular Disease Clinic, PA

    San Antonio, Texas · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.